European Journal of Medicinal Chemistry (2021)
Update date:2022-08-16
Topics:
Moir, Michael
Lane, Samuel
Montgomery, Andrew P.
Hibbs, David
Connor, Mark
Kassiou, Michael
The development of selective CB2 receptor agonists is a promising therapeutic approach for the treatment of inflammatory diseases, without CB1 receptor mediated psychoactive side effects. Preliminary structure-activity relationship studies on pyrazoylidene benzamide agonists revealed the -ylidene benzamide moiety was crucial for functional activity at the CB2 receptor. A small library of compounds with varying linkage moieties between the pyrazole and substituted phenyl group has culminated in the discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine agonist 19 (CB2R EC50 = 19 nM, CB1R EC50 > 10 μM). Docking studies have revealed key structural features of the linkage group that are important for potent functional activity.
View MoreZouping Mingxing Chemical Co.,Ltd.
website:http://www.zoutong.com.cn
Contact:86-543-2240068 2240067
Address:428 Daixi Third Road Zouping County Shandong Province China
Buffett (China) Holding Co.,Ltd
Contact:4006570891
Address:
HANGZHOU ZHONGCHANG SCIENTIFIC CO.,LTD
Contact:+86-571-88932183
Address:Hangzhou
shanghai jinshan pharmaceutical Co.,Ltd
Contact:021-57363011,13681638167
Address:No. 7966 Tingfeng Road,Jinshan,Shanghai,China
Contact:+86-371-86058576
Address:NO.32, Jingsan Road, Zhengzhou, China
Doi:10.1016/0039-128X(72)90021-9
(1972)Doi:10.1021/jacs.1c02622
(2021)Doi:10.1007/s00706-002-0505-8
(2003)Doi:10.1107/S0108270103001069
(2003)Doi:10.1016/j.tet.2019.130512
(2019)Doi:10.1177/1747519819868202
(2019)